Bookrunner Wells Fargo, co-managers Roth Capital and Griffin assisted
By Devika Patel
Knoxville, Tenn., July 27 – Fibrocell Science, Inc. said the underwriters for its public sale of stock opted to exercise the deal’s $2.32 million greenshoe in part, lifting total proceeds of the offering to $17.25 million. The deal was announced July 21 and priced for $15.08 million with the greenshoe on July 22.
The company sold 2,974,136 common shares at $5.80 per share. The price per share reflects a 0.86% discount to the July 21 closing share price of $5.85. Of the shares, 374,136 were part of the partially exercised greenshoe.
Wells Fargo Securities, LLC was the bookrunner.
Proceeds will be used for clinical and preclinical development and general corporate purposes.
Fibrocell is a biotechnology company based in Exton, Pa.
| Issuer: | Fibrocell Science, Inc.
|
| Issue: | Common stock
|
| Amount: | $17,250,000, including $2.17 million greenshoe of 374,136 shares
|
| Shares: | 2,974,136
|
| Price: | $5.80
|
| Warrants: | No
|
| Bookrunner: | Wells Fargo Securities, LLC
|
| Co-managers: | Roth Capital Partners and Griffin Securities
|
| Announcement date: | July 21
|
| Pricing date: | July 22
|
| Settlement date: | July 27
|
| Stock symbol: | Nasdaq: FCSC
|
| Stock price: | $5.85 at close July 21
|
| Market capitalization: | $271.44 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
